<SEC-DOCUMENT>0001193125-18-189948.txt : 20180612
<SEC-HEADER>0001193125-18-189948.hdr.sgml : 20180612
<ACCEPTANCE-DATETIME>20180612060604
ACCESSION NUMBER:		0001193125-18-189948
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180612
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180612
DATE AS OF CHANGE:		20180612

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		18893508

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d602525d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): June&nbsp;12, 2018 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Corporation plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">0-21392</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2 Pembroke House, Upper Pembroke Street <FONT STYLE="white-space:nowrap">28-32,</FONT> Dublin
2,</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ireland</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: +353 1 6699 020 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Former
name or former address, if changed since last report </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 (17 CFR <FONT STYLE="white-space:nowrap">&#167;240.12b-2).</FONT> </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01. Other Events. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;12, 2018, Amarin announced that it had entered into a collaboration agreement with Mochida Pharmaceutical Co., Ltd.
(&#147;Mochida&#148;), an integrated Japanese pharmaceutical company. The collaboration agreement is focused on the development and commercialization of early-stage drug products based on <FONT STYLE="white-space:nowrap">omega-3</FONT> acid EPA
(eicosapentaenoic acid). Under the collaboration agreement Amarin will, among other things, obtain an exclusive license to certain Mochida technology to develop, manufacture and commercialize new drug products that contain high purity EPA for the
United States and other territories. Under the collaboration agreement, Amarin will pay Mochida anon-refundable, <FONT STYLE="white-space:nowrap">non-creditable</FONT> upfront payment of $2.7&nbsp;million, and may be obligated to pay milestone
payments and royalties on net sales of future products arising from the collaboration, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amarin&#146;s management expects that
expenditures related to research and development activities for product candidates under the collaboration agreement will be immaterial in 2018 and less than $5.0&nbsp;million in 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A press release regarding the foregoing is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Exhibit&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; display:inline; font-size:8pt; font-family:Times New Roman; ">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d602525dex991.htm">Press Release, dated June&nbsp;12, 2018 </A></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-looking statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> contains forward-looking statements, including expectations regarding future clinical
development activities, drug development collaboration activities, and amounts to be incurred or payable in connection with the Mochida collaboration. These forward-looking statements are not promises or guarantees and involve substantial risks and
uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated with drug development and dependence of third parties. A further list and description of
these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin&#146;s filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q.</FONT> Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp; * &nbsp;&nbsp;&nbsp;&nbsp; * </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: June&nbsp;12,&nbsp;2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Amarin Corporation plc</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Thero</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John Thero</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d602525dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g602525g0612031555066.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amarin and Mochida Announce Collaboration on Future Development of </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">EPA-based</FONT> Drug Products and Indications </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BEDMINSTER, N.J. and DUBLIN, Ireland, June&nbsp;12, 2018 &#151; Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular health, announced today that it has entered into a multi-faceted collaboration with Mochida Pharmaceutical Co., Ltd. (&#147;Mochida&#148;, TYO:4534), an integrated Japanese
pharmaceutical company. The collaboration is focused on the development and commercialization of early-stage drug products and indications based on the <FONT STYLE="white-space:nowrap">omega-3</FONT> acid, EPA (eicosapentaenoic acid). Amarin and
Mochida are recognized worldwide as the leading, innovation-driven companies committed to the research and development of <FONT STYLE="white-space:nowrap">EPA-based</FONT> drug products to treat the needs of tens of millions of patients who are <FONT
STYLE="white-space:nowrap">at-risk</FONT> of cardiovascular disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin developed and markets
Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) capsules in the United States, the first and only <FONT STYLE="white-space:nowrap">FDA-approved,</FONT> prescription pure EPA drug product. Vascepa is indicated as
an adjunct to diet to reduce triglyceride levels in adult patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia. Amarin&#146;s clinical development program for Vascepa includes the <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> cardiovascular outcomes study, an <FONT STYLE="white-space:nowrap">8,175-patient</FONT> study commenced in 2011.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>
<FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> is the first multinational cardiovascular outcomes study evaluating the effect of prescription pure EPA therapy, or any triglyceride lowering therapy, as an
<FONT STYLE="white-space:nowrap">add-on</FONT> to statins in patients with high cardiovascular risk who, despite stable statin therapy, have elevated triglyceride levels <FONT STYLE="white-space:nowrap">(150-499</FONT> mg/dL). Amarin expects to
announce <FONT STYLE="white-space:nowrap">top-line</FONT> results of this landmark study before the end of Q3 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mochida is an integrated Japanese
pharmaceutical company that developed and markets a prescription pure EPA drug product, Epadel, as a treatment for hyperlipidemia and arteriosclerosis obliterans in Japan. Mochida sponsored and successfully completed a cardiovascular outcomes trial
with Epadel in Japan, JELIS. JELIS was the world&#146;s first large-scale randomized controlled cardiovascular outcomes trial of a prescription pure EPA drug product and showed beneficial effects of the drug in further reducing cardiovascular events
in statin-treated, hypercholesterolemic Japanese patients.<SUP STYLE="font-size:85%; vertical-align:top">2, 3, 4</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are excited to enter into
a collaboration with Mochida given our common mission to create preventative healthcare solutions on a worldwide basis, and our mutual commitment to continued innovation in the EPA research and development area,&#148; stated John F. Thero, president
and chief executive officer of Amarin. &#147;This collaboration seeks to leverage the decades of successful research and development experience at Amarin and Mochida towards expediting the development of new products and indications.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Mochida is delighted to partner with Amarin,&#148; stated Mr.&nbsp;Naoyuki Mochida, president of Mochida.
&#147;Both Mochida and Amarin have demonstrated strong capabilities in developing and commercializing <FONT STYLE="white-space:nowrap">EPA-based</FONT> products and we believe that together we can achieve much more to improve patient care in the
years to come.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among other terms in the agreement, Amarin obtained an exclusive license to certain Mochida intellectual property to advance
Amarin&#146;s interests in the United States and certain other territories and the parties will collaborate to research and develop new products and indications based on EPA for Amarin&#146;s commercialization in the United States and certain other
territories. The potential new product and indication opportunities contemplated under this agreement are in relatively early stages of development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amarin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc is a
biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin&#146;s product development program leverages its extensive experience in lipid science and the potential therapeutic
benefits of polyunsaturated fatty acids. Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl), Amarin&#146;s first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product, is a highly-pure, <FONT
STYLE="white-space:nowrap">omega-3</FONT> fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit <U>www.amarincorp.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Mochida </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mochida Pharmaceutical Co. Ltd. has been
committed to research and development of innovative pharmaceutical products since its establishment thereby providing distinctive medicines to the medical field. Currently, the core pharmaceutical business focuses resources on the targeted areas of
cardiovascular medicine, obstetrics and gynecology, dermatology, psychiatry and gastroenterology while also providing medicine for intractable disease as well as generics including biosimilars, to meet medical needs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mochida markets the world&#146;s first high-purity EPA drug, Epadel, developed and launched by Mochida as an ethical drug. Epadel has been the leading drug in
its class in Japan over the past two decades with indications of hyperlipidemia and arteriosclerosis obliterans. Epadel has been broadly studied in Japan including the JELIS study which was successfully conducted to investigate the long-term
administration of Epadel in statin-treated patients with hypercholesterolemia and the results are described as evidence-based medicine information on treatment with EPA pharmaceutical products in various clinical guidelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information about Mochida Pharmaceutical Co., Ltd., visit <U>http://www.mochida.co.jp/english/</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin&#146;s clinical development program for Vascepa includes a trial known as the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> cardiovascular outcomes
study, an <FONT STYLE="white-space:nowrap">8,175-patient</FONT> study commenced in 2011. <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> is the first multinational cardiovascular outcomes study evaluating the effect of prescription pure EPA
therapy, or any triglyceride lowering therapy, as an <FONT STYLE="white-space:nowrap">add-on</FONT> to statins in patients with high cardiovascular risk who, despite stable statin therapy, have elevated triglyceride levels <FONT
STYLE="white-space:nowrap">(150-499</FONT> mg/dL). A large portion of the male and female patients enrolled in this outcomes study are anticipated to also be diagnosed with type 2 diabetes. As reported previously, Amarin expects to announce <FONT
STYLE="white-space:nowrap">top-line</FONT> results of this important study before the end of Q3 2018. The <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> trial is being conducted under a Special Protocol Assessment agreement with the U.S. Food and
Drug Administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional information on clinical studies of Vascepa can be found at <U>www.clinicaltrials.gov.</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About VASCEPA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) Capsules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) capsules are a single-molecule prescription product consisting of the <FONT
STYLE="white-space:nowrap">omega-3</FONT> acid commonly known as EPA in ethyl-ester form. Vascepa is not fish oil, but is derived from fish through a stringent and complex <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> manufacturing process
designed to effectively eliminate impurities and isolate and protect the single molecule active ingredient. Vascepa, known in scientific literature as AMR101, has been designated a new chemical entity by the FDA. Amarin has been issued multiple
patents internationally based on the unique clinical profile of Vascepa, including the drug&#146;s ability to lower triglyceride levels in relevant patient populations without raising <FONT STYLE="white-space:nowrap">LDL-cholesterol</FONT> levels.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">FDA-Approved</FONT> Indication and Usage </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Important Safety Information for Vascepa </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vascepa is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of its components. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Use with caution in patients with known hypersensitivity to fish and/or shellfish. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The most common reported adverse reaction (incidence &gt; 2% and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo). There was no reported adverse reaction &gt; 3% and greater than placebo.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patients receiving treatment with Vascepa and other drugs affecting coagulation (e.g., anti-platelet agents) should be monitored periodically. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patients should be advised to swallow Vascepa capsules whole; not to break open, crush, dissolve, or chew Vascepa. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Adverse events and product complaints may be reported by calling <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-855-VASCEPA</FONT></FONT> or the FDA at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-FDA-1088.</FONT></FONT></FONT> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa has been approved for use by the United States Food and Drug Administration (FDA) as an adjunct to diet to reduce triglyceride levels in adult
patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia. Nothing in this press release should be construed as promoting the use of Vascepa in any indication that has not been approved by the FDA. In
particular, JELIS study results, while supportive of the potential for cardiovascular risk benefit in the statin-treated patients studied, are not to be directly extrapolated to apply to statin-treated patients in the United States due to various
elements in the JELIS study design and various differences in the patient populations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cardiovascular Disease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Worldwide, cardiovascular disease (CVD) remains the #1 killer of men and women. In the United States CVD leads to one in every three deaths &#150; one death
approximately every 38 seconds &#150; with annual treatment cost in excess of $500&nbsp;billion.<SUP STYLE="font-size:85%; vertical-align:top">5, 6</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beyond the cardiovascular risk associated with <FONT STYLE="white-space:nowrap">LDL-C,</FONT> genetic, epidemiologic, clinical and real-world data suggest
that patients with elevated triglycerides (TG) (fats in the blood), and <FONT STYLE="white-space:nowrap">TG-rich</FONT> lipoproteins, are at increased risk for cardiovascular disease. <SUP STYLE="font-size:85%; vertical-align:top">7, 8, 9, 10</SUP>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leading clinical investigations seeking to address cardiovascular risk reduction beyond lowering <FONT STYLE="white-space:nowrap">LDL-C</FONT> focus on
interrupting the atherosclerotic process (e.g., plaque formation and instability) by beneficially affecting other lipid, lipoprotein and inflammation biomarkers and cellular functions thought to be related to atherosclerosis and cardiovascular
events. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press
release contains forward-looking statements, including expectations regarding future clinical development activities, drug development collaboration activities and anticipated timing for the announcement of top line results from the <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> outcomes trial. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from
those described or projected herein include uncertainties associated with drug development and dependence of third parties. Importantly, the success of the JELIS study is not a guarantee of the success of the
<FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study due to a number of factors, risks and uncertainties inherent in complex clinical studies like JELIS and <FONT STYLE="white-space:nowrap">REDUCE-IT.</FONT> A description of these and other risks
and uncertainties associated with an investment in Amarin can be found in Amarin&#146;s filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT>
Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press
release, whether as a result of new information, future events or circumstances or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of Other Information About Amarin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and others should note that Amarin communicates with its investors and the public using the company website (<U>http://www.amarincorp.com/</U>), the
investor relations website (<U>http://investor.amarincorp.com/</U>), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The
information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels,
including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin&#146;s investor relations website and may include social media channels. The contents of Amarin&#146;s website or these
channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>References </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Miller M, Tardif <FONT STYLE="white-space:nowrap">J-C,</FONT> Ketchum SB, Doyle RT Jr, Murphy SA, Soni PN, Braeckman RA, Juliano RA, Ballantyne CM and on behalf of the <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> Investigators. Rationale and design of <FONT STYLE="white-space:nowrap">REDUCE-IT:</FONT> Reduction of Cardiovascular Events with Icosapent Ethyl&#150;Intervention Trial. <I>Clin</I> <I>Cardio</I>l.
2017;40:138&#150;148. https://doi.org/10.1002/clc.22692. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Yokoyama M, Origasa H, Matsuzaki M, et al for Japan EPA Lipid Intervention Study (JELIS) investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised
open-label, blinded endpoint analysis. <I>Lancet</I>. 2007;369(9567):1090-1098. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Saito Y, Yokoyama M, Origasa H, et al; for JELIS investigators, Japan. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors:
<FONT STYLE="white-space:nowrap">sub-analysis</FONT> of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). <I>Atherosclerosis</I>. <FONT STYLE="white-space:nowrap">2008;200(1):135-140.</FONT> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Matsuzaki M, Yokoyama M, Saito Y, et al; for JELIS investigators, Japan. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. <I>Circ J.
</I>2009;73(7):1283-1290. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>American Heart Association. 2018. Disease and Stroke Statistics-2018 Update. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">American Heart Association. 2017. Cardiovascular disease: A costly burden for America projections through 2035. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">7</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. <I>Am J Cardiol</I>. 2016;118:138-145. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">8</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Toth PP, Granowitz C, Hull M, et al. High triglycerides increase cardiovascular events, medical costs, and resource utilization in a real-world analysis of statin-treated patients with high cardiovascular risk and
well-controlled <FONT STYLE="white-space:nowrap">low-density</FONT> lipoprotein cholesterol [abstract]. <I>Circulation</I>. 2017;136(suppl 1):A15187. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">9</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease&#151;New insights from epidemiology, genetics, and biology. <I>Circ</I><I> Res</I>. 2016;118:547-563. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">10</SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. <I>Lancet.</I> 2014; 384: 626&#150;635. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin Contact Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investor Relations: </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elisabeth Schwartz </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin
Corporation plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (908) <FONT STYLE="white-space:nowrap">719-1315</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investor.relations@amarincorp.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lee M. Stern </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trout Group </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (646)
<FONT STYLE="white-space:nowrap">378-2992</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>lstern@troutgroup.com </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Media Inquiries: </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kristie Kuhl </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finn Partners </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (212)
<FONT STYLE="white-space:nowrap">583-2791</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kristie.kuhl@finnpartners.com </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g602525g0612031555066.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g602525g0612031555066.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] 2\# 2(  A$! Q$!_\0
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M01V(KE_@P,> E/K=2_S%>,>%/&-[X7:ZA3=+8W<;1S09[D$!AZ$5[3\&01X
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M;\6:/XQ^(6F:3)=(-%M9-S.QPDTHZ#/I7KR0VKJ"D<++C@JH(KE?^%5^#/\
MH"Q_]_'_ ,:WM$\/:9X=MY+?2[;R(I&W,N]FR?Q)K&;BTN4N*=]2]]F@[P1_
M]\"O,/C)HNEW'AU=222WAO;5P% 8 R*>HQWKU,@$$'H:Y>?X<^$KJ9II]&BD
MD=BS%G?DG\:4)*,KL<E=6/F.POI]-OX+VV<I- X=2/:OJ;POXJT_Q)HD%[#<
MQ"0J/.C+@,C=P15'_A6/@S_H V__ 'TW^-*OPS\'+G;HD*YZX=Q_6M:M2%0B
M$)1/!_B/<0W/C[5);>5)(S(!N0Y!('K7:? N[MX;S5HI9XTD=4*(S %@,YQ7
MH?\ PK'P;_T K?\ [Z;_ !H'PR\&@Y&AP ^H=_\ &G*M%PY1*G)2YCI[B"&]
MM)+>9%EAE0JRGD,#7RUXV\,2^%/$D]DP/V=SOMW_ +R'_"OJ2SM(+"TBM;:,
M1PQ+M102<#\:S]<\+Z-XD6(:M8I<^43L))!7/N*SI5.1^1<X<R/$_A/XY30;
M]M(U*8)I]RV8W<\1/_0&O6O'6H68\"ZJWVJ'#VY"XD'S9QT]:K_\*K\&?] 6
M/_OX_P#C3O\ A6'@XJ%.C1L!T!D<X_6JG.$I<R$HR2L?,&>*^H_ 6J6$_@C2
MO+NX28K=4<;QE2!@@CM4?_"KO!G_ $ X?^^W_P :4?##P<N<:+$,]<2/_C55
M:L*BL3"$HLX;XS>(--N)=(L;>YCFF@F\Z7RV#!%XZX[\5ZSI>I66I6,$]G=1
M3QN@*E&![5SW_"KO!G_0#A_[[?\ QJ[IG@7PUHU['>:?I4<%Q'G8ZNW&1@]\
M=ZSE*#BDNA:4KW9T55M0T^UU2PFLKV%9K>92KHPX(JS1619\P>/? MUX.U+*
MAI=,F;]Q/CI_L-[C]:]A^#H(^']OGO-(1^==CJNE66MZ;-I]_"LUO,N&4]O<
L>A'K57PWX>M/"^CIIED\KP(Q8&5@6Y.>PK:=7GA9[F<:?+*Z->BBBL30_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
